Medicare AdvantageCoverageHigh impact
MA08.007aw, Medicare Part B vs. Part D Crossover Drugs
Independence Blue Cross·Pharmacy·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 8, 2026
Summary
Policy MA08.007aw addresses Medicare Advantage coverage distinctions between Part B and Part D crossover drugs—medications that can be covered under either pharmacy (Part D) or medical benefit (Part B) depending on administration method and clinical context. This policy clarifies billing and coverage rules to prevent improper claim routing and ensure correct benefit application for affected drugs.
Action Required
By June 30, 2026: Billing team must review MA08.007aw policy documentation to identify which drugs in your practice's formulary are classified as Part B vs. Part D crossover medications. Update billing system logic and claim routing protocols to ensure drugs administered in-office are billed to Part B medical benefit, while patient-administered drugs are routed to Part D pharmacy benefit. Revise prior authorization workflows and encounter documentation templates to capture administration method and site of service. Train clinical and billing staff on the distinction—claims routed to wrong benefit will be denied and require reprocessing. Notify providers of any changes to drug billing protocols before the effective date.